Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- Pharmacology’s Krzysztof Palczewski recognized for advancements in vision care
- Pathology’s Beno Michel to receive honorary fellowship from The Hebrew University of Jerusalem
- CWRU Baja Team has best performance in its history
- CWRU receives grant to give students opportunity to study abroad in Ireland
- Enhance spoken English skills with seminar series